Changsha Wanwei Technology Co., Ltd.

Changsha Wanwei Technology Co., Ltd. has been deeply engaged in the biopharmaceutical industry for over 20 years and stands as a global leader in the metabolic disease drug sector. Leveraging its integrated end-to-end capabilities covering "R&D, production, and commercialization" as well as profound industry expertise, the company firmly ranks among the top tier of the global biopharmaceutical industry. Its core products include multiple key varieties such as Semaglutide, Tirzepatide, Retatrutide, and Cagrilintide.​Eighty percent of the members in the company's core team possess over 15 years of experience in metabolic drug R&D. Many of them have led the launch of internationally blockbuster antidiabetic drugs. The team has successfully facilitated the approval of 12 innovative drugs, among which 5 have become top 50 best-selling prescription drugs globally. This has enabled the company to establish an irreplicable technical and experiential barrier in fields such as peptide drug molecular modification and long-acting formulation development.​On the R&D front, the company has built four national-level technology platforms, including peptide molecular design and oral formulation innovation, and holds more than 300 authorized patents. Its drug R&D cycle is 30% shorter than the industry average. On the production side, it owns the world's largest intelligent base for peptide drugs, with an annual production capacity of 500 kilograms. The base complies with the triple GMP standards of China, the United States, and the European Union, and achieves a 90% self-sufficiency rate in key raw materials, ensuring stable supply to over 120 countries. Additionally, the company has passed the unannounced inspections by the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) for 10 consecutive years.​Currently, Semaglutide has overcome the challenge of low oral bioavailability, achieving global sales of over 15 billion US dollars within 3 years of its launch. Tirzepatide surpassed 8 billion US dollars in sales in its first year on the market. Retatrutide has entered Phase III clinical trials, while the combination therapy of Cagrilintide is in Phase II clinical development. All these products demonstrate revolutionary therapeutic value. Looking ahead, the company will invest 25% of its annual revenue in R&D, focusing on the fields of metabolism and cardiovascular diseases, and is committed to becoming a global innovation benchmark in the biopharmaceutical industry.